The Treatment of Hallucinations in Schizophrenia Spectrum Disorders by Sommer, I.E.C. et al.
The Treatment of Hallucinations in Schizophrenia Spectrum Disorders
Iris E. C. Sommer1,*, Christina W. Slotema2, Zafiris J. Daskalakis3,4, Eske M. Derks1, Jan Dirk Blom2,5, and
Mark van der Gaag2,6
1Neuroscience Division, Psychiatry Department, University Medical Centre Utrecht & Rudolf Magnus Institute of Neuroscience,
University Medical Center Utrecht, PO Box 85500, 3508 GA, Utrecht, the Netherlands; 2Parnassia Bavo Group, The Hague, the
Netherlands; 3Department of Psychiatry, University of Toronto, Toronto, Canada; 4Centre for Addiction and Mental Health, Toronto,
Canada; 5Department of Psychiatry, University of Groningen, Groningen, the Netherlands; 6VU University and EMGOþ Institute for
Health and Care Research, VU University, Amsterdam, the Netherlands
*To whom correspondence should be addressed; tel: 31-88-75-56365, fax: 31-88-75-56543, e-mail: i.sommer@umcutrecht.nl
This article reviews the treatment of hallucinations in
schizophrenia. The first treatment option for hallucina-
tions in schizophrenia is antipsychotic medication, which
can induce a rapid decrease in severity. Only 8% of first-
episode patients still experience mild to moderate
hallucinations after continuing medication for 1 year.
Olanzapine, amisulpride, ziprasidone, and quetiapine
are equally effective against hallucinations, but haloper-
idol may be slightly inferior. If the drug of first choice
provides inadequate improvement, it is probably best
to switch medication after 2–4 weeks of treatment.
Clozapine is the drug of choice for patients who are
resistant to 2 antipsychotic agents. Blood levels should
be above 350–450 mg/ml for maximal effect. For
relapse prevention, medication should be continued in
the same dose. Depot medication should be considered
for all patients because nonadherence is high. Cogni-
tive-behavioral therapy (CBT) can be applied as an
augmentation to antipsychotic medication. The success
of CBT depends on the reduction of catastrophic
appraisals, thereby reducing the concurrent anxiety
and distress. CBT aims at reducing the emotional
distress associated with auditory hallucinations and
develops new coping strategies. Transcranial magnetic
stimulation (TMS) is capable of reducing the frequency
and severity of auditory hallucinations. Several meta-
analyses found significantly better symptom reduction
for low-frequency repetitive TMS as compared with
placebo. Consequently, TMS currently has the status
of a potentially useful treatment method for auditory
hallucinations, but only in combination with state of
the art antipsychotic treatment. Electroconvulsive ther-
apy (ECT) is considered a last resort for treatment-
resistant psychosis. Although several studies showed
clinical improvement, a specific reduction in hallucina-
tion severity has never been demonstrated.
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Introduction
Schizophrenia can be accompanied by hallucinations in
any of the sensory modalities. In 70% of the cases they
are auditory in nature, and in 50% of those cases visual
hallucinations are also experienced at some point. Other
types of hallucination are less prevalent. But whatever
the sensory modality in which they are experienced, hallu-
cinations can be such a burden that they require expert
treatment. Treatment usually consists of psychoeducation,
medication, psychosocial interventions, psychotherapy,
and in some instances transcranial magnetic stimulation
(TMS) or electroconvulsive therapy (ECT).
The present article will focus on medication, cognitive-
behavioral therapy (CBT), TMS, and ECT. We will sum-
marize the existing literature and offer recommendations
for the treatment of hallucinations in schizophrenia.
Pharmacological Treatment of Hallucinations in
Schizophrenia Spectrum Disorders
The only type of medication known to effectively reduce
the frequency and severity of hallucinations in schizophre-
nia spectrum disorders is antipsychotic medication. So far,
no clinical trials have been published that compare the
efficacy of various antipsychotic drugs for the sole and
specific indication of hallucinations. Therefore, we used
the data from the European First-Episode Schizophrenia
Trial (EUFEST) to assess the potential of 5 antipsychotic
agents to reduce the severity of hallucinations.
The EUFEST study1 included 498 patients with
a first-psychotic episode, who were randomized to receive
haloperidol, olanzapine, amisulpride, quetiapine, or
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ziprasidone. The reduction in total symptom severity was
virtually the same in all groups, around 60% after 12
months of treatment, but differences were observed in
the discontinuation rate, which was higher for
haloperidol and lower for amisulpride and olanzapine.1
We reanalyzed these data with item P3 (severity of
hallucinations) of the Positive and Negative Syndrome
Scale,2 as the primary outcome measure.
All subjects with a score of 3 or higher at baseline
(indicating at least mild hallucinations) were included
(N = 362; 73% of the total sample). Even though 54%
of the patients discontinued treatment within 12 months,
unbiased parameter estimates were obtained under the
assumption of Missing at Random. A mean reduction
in the severity of hallucinations from 4.4 at baseline, in-
dicating marked to severe hallucinations, to a mean value
of 2.5, indicating minimal to mild hallucinations, was
found after 4 weeks. The severity of hallucinations
continued to decline with prolonged treatment to mean
values of around 1.5, reflecting the presence of absent
to minimal hallucinations after 6 months of treatment
(see figure 1). Likewise, the percentage of subjects with
at least mild levels of hallucinations decreased strongly
over time from 100% at baseline to 8% after 12 months
of treatment. These findings indicate that hallucinations
in patients with a psychotic disorder respond fairly well to
antipsychotic treatment, showing a strong reduction in
symptom severity in the first month.
These results should be encouraging for patients who
suffer from hallucinations, and it might help them decide
to start and continue pharmacotherapy. We investigated
differences in the efficacy of the 5 antipsychotic agents by
comparing the fit of a model in which the mean reduction
in hallucinations is constrained to be equal across groups
with the fit of a model in which reduction in hallucina-
tions is allowed to be different across groups. Results in-
dicated that there was no significant difference in efficacy
between haloperidol, olanzapine, ziprasidone, quetia-
pine, and amisulpride in their potential to combat hallu-
cinations (v2(4) = 7.90, P = .095). Even though the
difference between groups is not significant, we compared
the steepness of the growth curves (shown in figure 1)
as the difference between treatment arms could be con-
sidered a trend finding. This revealed that haloperidol
showed less reduction in hallucinations compared with
the other antipsychotic agents. The largest difference
was found between haloperidol and olanzapine
(v2(1) = 6.93, P = .008) which is not significant after Bon-
ferroni correction for the 15 comparisons which have
been made (ie, testing at a type I error rate if .003).
This finding should therefore be interpreted with caution.
With regards to their side effects, antipsychotics can be
divided roughly into those predominantly inducing
weight increase and sedation (ie, quetiapine, olanzapine,
and clozapine) and those frequently associated with dys-
tonia, parkinsonism, and akathisia (ie, all other antipsy-
chotic drugs). The Patient Outcomes Research Team
guidelines do not recommend olanzapine or clozapine
as drugs of first choice because of the severe weight
gain they may induce.3 Yet, a recent Finnish study found
that the use of these 2 antipsychotics was associated with
lower rates of rehospitalization, suggesting better efficacy
and/or adherence over other antipsychotics.4
If remission is not obtained with the drug of first
choice, a relatively quick switch is warranted. The exact
moment for such a switch is still under discussion, but
there is cumulating evidence that antipsychotic drugs re-
quire only little time (in the order of hours rather than
days or weeks) to manifest their potential.5 This would
imply that a switch can be considered after 2 or 4 weeks
of treatment. A second antipsychotic is usually chosen
from the group of drugs with a different receptor profile,
although direct evidence to support this strategy is
scarce.3 For those patients who even fail to respond to
a second antipsychotic agent, clozapine is considered
the drug of choice. The landmark trial by Kane et al6
demonstrated superior efficacy of clozapine for the sub-
group of medication-resistant patients in comparison
with any other antipsychotic agent, a finding that has
consistently been replicated.7 In order to optimize cloza-
pine therapy, various studies have evaluated the relation-
ship between clozapine blood levels and therapeutic
response. Blood levels above 350–450 lg/ml are associ-
ated with superior treatment results, not only for intrac-
table hallucinations but also for negative symptoms,
disorganized behavior, and thought disorder.7 Despite
these unique qualities, clozapine has failed to gain the
status of a drug of first or second choice as a result of
its rare, but potentially severe side effects.
Fig. 1. Mean decrease in hallucination severity (item P3 of the
Positive and Negative Syndrome Scale [PANSS]) in first-episode
patients with a nonaffective psychotic disorder after 1, 3, 6, 9, and 12
months on antipsychotic medication.
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Maintenance Treatment
When successful, antipsychotic medication should be
prescribed for patients with schizophrenia in an unal-
tered dose for at least 1 year.3 However, this does not
imply that the treatment should be discontinued as
soon as the year is over. As the propensity to hallucinate
depends for the greater part on our genetic makeup, the
vulnerability for hallucinations is life long. Therefore, as
long as the side effects are tolerable, it is preferable not
to discontinue the medication that has led to the initial
improvement, not even after a prolonged psychosis-free
period.
To prevent relapses, 2 strategies can be followed: con-
tinuous maintenance treatment with antipsychotic
medication, or intermittent treatment, to be started
as soon as any signs of potential relapse are detected.
In a randomized study, maintenance treatment was
found to be more effective than targeted intermittent
treatment in preventing relapse, even in stable patients
after their first year of maintenance treatment.8 There
has been considerable discussion regarding the optimal
dose for maintenance treatment. In an elegant study,
Wang et al9 randomized 404 patients with schizophre-
nia in remission to 3 conditions: I. Initial optimal ther-
apeutic dose continued throughout the study, II. Initial
optimal therapeutic dose continued for 4 weeks and
then reduced to 50%, and III. Initial optimal therapeu-
tic dose continued for 6 months and then reduced to
50%. After 1 year, the relapse rates were 9.4% for group
I, 30.5% for group II, and 19.5% for group III. These
findings indicate that a dose reduction of 50% increases
the risk for relapse 2- or 3-fold. Whether a dose reduc-
tion of less than 50% is as effective as continuation of
the initial dose remains unclear. Current evidence thus
suggests that continuous maintenance treatment with
the initial dose used for symptom remission provides
the lowest relapse rates.
Depot Medication
As relapses of hallucinatory episodes are most frequently
associated with nonadherence to antipsychotic treat-
ment,10 long-acting injectables (the so-called ‘‘depots’’)
constitute a valuable alternative for oral medication.
Studies comparing short-acting oral and long-acting in-
jectable antipsychotics found the latter to be superior in
terms of relapse prevention and improvement of social
functioning.11 In parallel, a large population–based study
found in a pair-wise comparison between depot injections
and their equivalent oral formulations, the risk of reho-
spitalization for patients receiving depot medications to
be about one-third of that for patients receiving oral med-
ications.4 Therefore, depot medication may be beneficial
to prevent relapse in many patients and should be
explained as an option for maintenance treatment to
all patients.
Poor Response to Antipsychotic Medication
Although clozapine is considered the most effective
antipsychotic agent for patients with refractory halluci-
nations, not all patients can achieve remission, even
with adequate blood levels of clozapine.6 Treatment of
these patients has remained a persistent public health
problem because they often have a low quality of life.
For these ultra-resistant patients, several treatment strat-
egies are available, including psychotherapy, pharmaco-
logical augmentation, repetitive TMS (rTMS), and ECT.
In clinical practice, clozapine is often augmented with
lithium, sodium valproate, benzodiazepines, selective
serotonin reuptake inhibitors, lamotrigine, risperidone,
haloperidol, or aripiprazole. A recent meta-analysis
quantitatively summarized all randomized controlled
trials (RCTs) involving the pharmacological augmenta-
tion of clozapine.12 That review included 29 RCTs
reporting on 15 different augmentation strategies pre-
scribed to 1066 patients in total. Better improvement
of total symptom severity—in comparison with place-
bo—was found for lamotrigine, sulpiride, citalopram,
and the glutamatergic agonist CX516. However, the
superiority of lamotrigine and topiramate turned out
to depend on the inclusion of a single outlier, whereas
the claim of superiority of sulpiride, citalopram, and
CX516 was based on single RCTs. We must conclude,
therefore, that pharmacological augmentation strategies
in clozapine therapy are not (yet) supported by much
convincing evidence from the literature.
Cognitive-Behavioral Therapy
CBT for Auditory Verbal Hallucinations
Auditory verbal hallucinations (AVH) occurring in the
context of psychotic disorders can be characterized by
5 specific aspects: the content of the voices is personally
meaningful, the voices have a more or less fixed identity,
the relationship with the voices tends to be intimate, the
experience has a significant impact on the patient’s life,
and the experience has a compelling sense of reality.13
All these aspects are targeted in CBT.
The application of CBT is based on a cognitive model of
auditory hallucinations.14 The classic cognitive-behavioral
model hinges on the way hallucinations are appraised.
Appraisals that tend to aggravate the severity of hallucina-
tory experiences are those that exaggerate their power,
characterize them as omnipotent and omniscient, place
their source in the external world, and endow them with
malevolent intentions. CBT targets the ways in which
the voices are being appraised. It puts the appraisals in per-
spective through a collaborative approach, in which other
possible explanations for the origin and meaning of voices
are considered together with the patient.
The behavioral part involves the testing of alternative
ways to deal with particular situations as well as
attempts to change the patient’s feelings about them.
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As soon as the patient starts to show any signs of doubt,
it is time to encourage behavioral changes such as
limiting the time spent with the voices, picking up
routines of daily life again, and attempting to regain
important social roles that lend meaning and fulfillment
to life. Also, safety behaviors must be broken down in
order to promote the experience that any anticipated
disastrous consequences fail to happen.
CBT has some new developments, sometimes referred
to as third wave therapies. We will also discuss compas-
sionate mind training (CMT), imagery techniques such as
competitive memory training (COMET), acceptance and
commitment therapy (ACT), and the application of eye
movement desensitization and reprocessing (EMDR) in
people with psychosis, and posttraumatic stress disorder
(PTSD).
The Effectiveness of CBT for Hallucinations
The effectiveness of CBT for hallucinations and other
psychotic symptoms is well documented in several
meta-analyses. A recent meta-analysis reported overall
beneficial effects for the target symptom (33 studies; ef-
fect size 0.40) as well as significant effects for positive
symptoms (32 studies), negative symptoms (23 studies),
general functioning (15 studies), mood (13 studies),
and social anxiety (2 studies) with effect sizes ranging
from 0.35 to 0.44. Although 32 studies reported signifi-
cant effects for positive symptoms, only 26 specifically
targeted positive symptoms. One study aimed to reduce
compliance with command hallucinations and reported
an effect size of 1.1.15 Group therapy, however, has
not yielded any clinically significant results.16 Involving
family members in the cognitive treatment of hallucina-
tions, on the other hand, turns out to be quite effective,
with long-lasting results and effect sizes ranging from
0.51 to 0.60.17
The Effectiveness of Content-Specific CBT for
Hallucinations
The specific content of auditory hallucinations has con-
sequences for the emotional responses to them and may
warrant various changes to the basic treatment protocol.
We will discuss specific treatment approaches for com-
mand hallucinations, humiliating voices, critical voices,
and voices associated with traumatic experiences and
PTSD.
CommandHallucinations. Threatening voices and com-
mand hallucinations can pose a serious threat to the pa-
tient and his environment. Fortunately, many patients
resist dangerous and aggressive commands of the voices,
but some will comply with the commands. By changing
patients’ beliefs about the power of their voices, the risk
that they will comply with command hallucinations can
be reduced. Trower and colleagues18 tested the effective-
ness of cognitive therapy for command hallucinations by
randomizing 38 patients who had recently complied with
their voices’ commands and had suffered the consequen-
ces. The control condition was treatment-as-usual, and
the patients were followed-up after 6 and 12 months.
In the cognitive-therapy group, the authors found large
and significant reductions in compliant behavior, with an
effect size of 1.1 (Cohen’s d). Improvements were
recorded in the treatment group (but not in the control
group) regarding the power attributed to the voices,
the perceived need to comply, and the levels of concom-
itant distress and depression. No changes in the fre-
quency, loudness, and content of the voices were
recorded. The differences were still significant at 12
months follow-up.
HumiliatingVoices. Some voices may constantly humil-
iate the patient by telling him that he is a loser, that no-
body cares for him, that he is incompetent, or that he
would be better off dead. Patients who experience such
humiliating voices also tend to feel depressed and helpless
and to ruminate about what they say.19 They often agree
with the content of their voices. COMET is based on the
notion that a therapy is successful when it changes the
hierarchy of relevant neural networks, and the order in
which those networks are activated. A successful treat-
ment reinforces the neural networks that are incompati-
ble with so-called ‘‘negative’’ networks. When instead
‘‘positive’’ networks are activated over and over again,
they may well move up in the hierarchy of networks
and come to surpass the negative ones. COMET teaches
the patient to reexperience personal memories that are
incompatible with the dominant voices’ messages. Ap-
plied to hallucinations, COMET primarily reduces de-
pression, with a medium to large effect size (Cohen’s
d = 0.64). That effect is mediated by the improvement
of self-esteem and the acceptance of the voices. The effect
on the auditory hallucinations scale of the Psychotic Rat-
ing Scales (PSYRATS) was nonsignificant (P = .197;
Cohen’s d = 0.30), while the effect on the cognitive inter-
pretation subscale measuring the appraisal of the voices
was significant (P = .009; Cohen’s d = 0.63).20
CriticalVoices. Critical voices are sometimes talking di-
rectly to the patient and sometimes to each other while
discussing the patient or gossiping about him, thus con-
stantly criticizing what the patients does or thinks. CMT
targets shame and self-criticism, as well as the ensuing
submissiveness and negative affect. With the aid of the
2-chair technique, a criticizing voice (or ‘‘inner bully’’)
can be interviewed, and the criticisms can then be com-
pared with the patient’s personal needs and distresses.
The patient is encouraged to respond toward himself
with warmth and compassion rather than with criticism.
Case-series reports are promising,21 and an RCT is
underway.
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Reperceptive or Memory-Based Hallucinations. Eleven
to 52% of those diagnosed with schizophrenia also
have comorbid PTSD.22 Victimization, especially in
the context of sexual traumatization, results in a 10-
fold likelihood to develop hallucinations and other psy-
chotic symptoms.23 The hallucinations experienced by
those patients can perhaps best be characterized as reex-
periences of a trauma. Memory processes probably medi-
ate such reperceptive hallucinations, whereas command
hallucinations may be predominantly attributable to inner
speech processes.24 Reperceptive hallucinations can be
treated effectively with the aid of CBT, exposure, and
EMDR. Mueser and colleagues25 carried out an RCT
with CBT and found effect sizes of 0.59 for the reduction
of the total symptom score. In an open trial with 20
patients, 12 patients ceased to fulfill the diagnostic criteria
of PTSD after prolonged exposure.26 In an open trial with
EMDR among 27 patients, within-group effect sizes of
1.16 were found for the total trauma symptoms score (Cli-
nician Administered PTSD Scale), 0.85 for depression
(Beck Depression Inventory), and 0.79 for anxiety
(Beck Anxiety Inventory). Eight people were hearing voi-
ces and 5 of them stopped hearing voices after EMDR.22
Acceptance and Commitment Therapy
Yet another type of treatment is ACT. This is a third
wave CBT and is a transdiagnostic therapy aimed (1)
at the acceptance of symptoms such as voices as mental
phenomena, (2) a reduction of the patient’s investment in
his symptoms, and (3) an increased commitment to im-
portant real-life goals and activities. An RCT by Bach
and Hayes27 unexpectedly found an increase in reported
hallucinations, but this was associated with a 50% de-
crease in rehospitalization rate compared with treatment
as usual.
TMS for Hallucinations in Schizophrenia
What is TMS?
TMS is a technique in which a strong pulse of electrical
current is sent through a coil. When the coil is placed over
a person’s skull, this induces a magnetic field pulse in
a small brain area, depolarizing local neurons up to
a depth of 2 cm. When TMS is applied repetitive, it is
thought to induce longer-lasting effects as a result of
long-term potentiation or depression at the neuronal
level.28 TMS is noninvasive, has only few side effects,
and is relatively safe. In the past, epileptic seizures
have occurred when rTMS was applied at a relatively
high frequency, for a long duration of time or at
a high percentage of the individual motor threshold.
However, since Wassermann29 developed specific safety
guidelines, seizures have become extremely rare. Side
effects such as headache, local discomfort due to direct
stimulation of the facial musculature, and transient
changes in the auditory threshold have been described.
In order to prevent the latter, earplugs are recommended
during rTMS treatment.
TMS for AVH
In 1999, Hoffman and colleagues30 started to explore
rTMS for the treatment of AVH. When the coil was
directed at the left temporoparietal cortex, they were
able to ameliorate medication-resistant AVH. Since
then, more studies on this subject have been published,
mostly—although not exclusively—carried out among
patients diagnosed with schizophrenia. The results of these
studies have been summarized in 4 meta-analyses, which
all conclude that rTMS has a moderate to good effect
on AVH, with effect sizes ranging from 0.51 to
1.04.31–34 However, a note of caution may be in place
here. When new treatment strategies are being introduced,
the initial reports tend to feature relatively small sample
sizes and favorable results, whereas small studies with neg-
ative findings do not tend to be published. With an
increase of studies with larger sample sizes in a later phase,
negative findings tend to become published as well. In
other areas of research, such trends have led effect sizes
to decrease per year of publication.35 As rTMS is a rela-
tively young treatment method, future studies may well
show less favorable results than the initial ones. Thus it
is no surprise that in our latest meta-analysis, we indeed
found a trend toward larger studies being published in re-
cent years, yielding negative results.36 We therefore take
into account that the initially reported positive effects
may perhaps disappear when more studies with larger
patient samples will be published. Nevertheless, the pres-
ent state of evidence allows us to recommend low-
frequency rTMS directed at the left temporoparietal
area for the treatment of AVH, although always in com-
bination with state of the art pharmacological treatment.
Alternative TMS Paradigms
Only few studies have examined the effects of low-
frequency rTMS targeted at other brain regions than
the left temporoparietal cortex. Lee and colleagues37
reported a reduction in the severity of AVH after rTMS
directed at the right temporoparietal cortex, which was
not replicated by others. rTMS directed at the left and
right temporoparietal cortex38 and rTMS directed at
foci with maximal hallucinatory activity, as indicated by
functional MRI,39 were not superior to sham treatment.
Furthermore, the effects of rTMS applied to either Broca’s
area or to the left superior temporal gyrus were equal to
those of sham treatment.39 No firm conclusions can be
drawn due to the small number of studies, but there is cur-
rently no evidence to suggest that locations other than the
left temporoparietal cortex are suitable options for the
treatment of auditory verbal hallucinations with rTMS.
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In the majority of studies, rTMS was applied with a fre-
quency of 1 Hz. But high-frequency rTMS has also been
studied as a treatment option for AVH, yielding a strong
clinical response with a frequency of 20 hertz. However,
the patient sample was small, and no control condition
was included, which precludes any firm conclusions regard-
ing this type of treatment too.40 A recent study from the
Utrecht group assessed 20-Hz stimulation and 1-Hz-stimu-
lation in a double-blind head-to-head comparison, and
found no differences between the 2 treatment arms
(De Weijer, A.D., Meijering, A.L., Bloemendaal M.,
et al., unpublished data). In a RCT, the effects of low-
frequency rTMS preceded by 5 minutes of 6-Hz rTMS
(priming) was compared with low-frequency rTMS, and
again no differences could be revealed between the 2 condi-
tions (Slotema, C.W., Blom, J.D., De Weijer, A.D., et al.,
unpublished data). Two case reports described relief from
chronic intractable auditory hallucinations after bilateral
andcontinuoustheta-burst-TMS,respectively.41,42However,
beforeanylargesham-controlledRCTswithfavorableresults
becomes available, we will not be able to recommend high-
frequency or theta-burst stimulations for the treatment of
AVH.
The majority of studies have been performed with the
aid of a figure-of-eight coil. H-coils, which have the shape
of a helmet, are designed to maximize the electrical current
induced in deep brain tissues by their ability to summate
separate magnetic fields projected into the skull from sev-
eral points around its periphery. In an open-label study, 8
patients were treated with deep-brain rTMS using such an
H-coil, which resulted in a significant reduction in the se-
verity of AVH.43 However, this study also lacked a control
group. As a consequence, its results need to be replicated
in randomized, placebo-controlled double-blind studies
before any conclusions can be drawn.
Electroconvulsive Therapy for Hallucinations in
Schizophrenia
Another augmentation strategy for the treatment of in-
tractable hallucinations occurring in the context of psy-
chosis is electroconvulsive therapy (ECT). Introduced as
a treatment method with highly promising results during
the 1930s and subsequently discarded during the 1970s,
ECT is now a well-established psychiatric treatment
method. It nevertheless continues to be the most stigma-
tized therapeutic in psychiatry, although for a limited
number of indications (notably catatonia and severe de-
pression), it can be extremely effective and potentially life
saving.
What is ECT?
During ECT, an electrical current is passed briefly
through the brain via electrodes attached to the scalp
to induce a generalized seizure. ECT is performed under
general anesthesia; muscle relaxants are administered to
prevent body spasms. The ECT electrodes can either be
placed on both sides of the head (bilateral placement) or
on one side only (unilateral placement). Unilateral place-
ment is usually over the nondominant half of the brain,
with the aim to reduce cognitive side effects. However,
bilateral electrode placement tends to yield a faster im-
provement. The amount of current required to induce
a seizure (called the seizure threshold) can vary largely
among individuals and may increase during the course
of treatment. Cognitive impairments, especially memory
problems, can occur immediately after the administration
of ECT as well as afterward. However, pretreatment
functioning levels tend to be reached within the first
months following treatment.44
Although ECT has been used in clinical practice since
the 1930s, there is still no generally accepted hypothesis
explaining its mechanism of action. In rat models, ECT
(contrary to antidepressants) can induce mossy fiber
sprouting, and there is growing evidence that it impacts
brain-derived neurotrophic factors capable of inducing
neuroproliferation.45
ECT for Hallucinations
There is no consistency whether persistent hallucina-
tions in psychosis should be considered a valid indica-
tion for ECT. Recently, the National Institute of
Clinical Excellence (NICE) concluded that ‘‘the current
state of the evidence does not allow the general use of
ECT in the management of schizophrenia to be recom-
mended.’’46 Understandably, only a low number of
studies have assessed the effects of ECT in a double-
blind sham-controlled design. Tharyan and Adams47
published a systematic meta-analysis of double-blind
randomized studies comparing ECT and antipsychotic
medication to sham and medication. They included
10 RCTs with a total of 392 patients. The relative risk
for clinical improvement was 0.78 in favor of real
ECT, a significant finding.
However, it should be noted that none of the above-
mentioned studies provided any details on the reaction
of hallucinations to ECT specifically. As a consequence,
the reported clinical improvement in all those studies is
not necessarily attributable to a reduction in the severity
of psychosis. In fact, we were unable to retrieve a single
study demonstrating a specific relief of hallucinations in
medication-resistant schizophrenia caused by ECT. As
a consequence, we must conclude that ECT as an aug-
mentation to antipsychotic medication is capable of im-
proving the clinical status of some patients with
medication-resistant psychosis, but this may be attribut-
able to other symptoms (mood, motor retardation, agi-
tation, and catatonia) than the core psychotic
symptoms. The effect of ECT on hallucinations per se
is as yet unclear and might well be low.
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Conclusions
Hallucinations in individuals diagnosed with schizophrenia
are usually treated with antipsychotic medication.
Antipsychotic medication is capable of inducing a rapid
decrease in hallucination severity, and only 8% of the
first-episode patients go on to experience mild, moderate,
or severe hallucinations when they continue their medi-
cation as prescribed during 1 year. Olanzapine, sulpride
ziprasidone, and quetiapine appear to be equally effective
against hallucinations, but haloperidol may not be the
agent of first choice. If the drug of first choice does
not provide adequate symptom reduction, it is probably
best to switch to another antipsychotic agent at a rela-
tively early stage (ie, after 2 to 4 wk). Clozapine dosed
to induce blood levels above 350–450 lg/ml, is the
drug of choice for patients who are resistant to 2 other
antipsychotic agents. For the sake of relapse prevention,
the same drug that induced remission should be contin-
ued, preferably in the same dose. Depot medication
should be considered for all schizophrenia patients, as
nonadherence is high among individuals thus diagnosed,
as is the chance of relapse.
CBT can be applied as an augmentation to antipsy-
chotic medication for all psychotic patients who experi-
ence hallucinations. The success of CBT depends on the
reduction of catastrophic appraisals, thereby reducing
concurrent anxiety and distress. CBT teaches the patient
to ignore the voices and focus on future plans and aims
that will increase their quality of life. It should be noted,
however, that CBT does not generally reduce the
frequency of hallucinations.
TMS, on the other hand, is capable of actually reduc-
ing the frequency and severity of auditory hallucinations.
Several meta-analyses found significantly better symp-
tom reduction when low-frequency rTMS was applied
to the left temporoparietal area (as compared with pla-
cebo), with only transient and mild side effects. Yet,
larger studies with lower effect sizes have recently been
published, and future meta-analyses may not be able
to replicate the positive main effects initially reported.
As a consequence, TMS currently has the status of a po-
tentially useful treatment method for auditory hallucina-
tions, but only in combination with state of the art
antipsychotic treatment.
Several guidelines mention electroconvulsive therapy
as a last resort for treatment-resistant psychosis in
schizophrenia patients. Although several double-blind
sham-controlled studies showed improvement in overall
symptom severity as compared with sham treatment,
a specific reduction in hallucination severity has never
been described at group level.
The Treatment of Hallucinations in Other Disorders
Hallucinations occur in the context of many different dis-
orders and syndromes. Therefore, the choice for a specific
type of treatment does not only depend on the type of
hallucination and its consequences for daily functioning
but also on the underlying disorder. It may be difficult,
however, to determine what the underlying disorder is, as
hallucinations in for example borderline-personality dis-
orders,48 psychotic depression, or temporal lobe epi-
lepsy49 may be indistinguishable from schizophrenic
hallucinations on the phenomenological level. Accompa-
nying symptoms, such as epileptic insults, parkinsonian
motor symptoms, vision or hearing loss, are the most re-
liable anchors for differential diagnosis.50 Some individ-
uals who hallucinate only sporadically may be merely
concerned that their experiences are a sign of mental dis-
ease, without being troubled by the hallucinations them-
selves. For others, the burden of their hallucinations may
not outweigh the side effects of treatment. As a conse-
quence, treatment may not be necessary in all cases. In
this paragraph, a few disorders that frequently present
with hallucinations will be discussed together with the
specific treatment options.
Hallucinations and other psychotic symptoms are com-
mon in patients with Parkinson’s disease (PD), with life-
time prevalence rates of up to 80%.51 In Lewy body
dementia, a condition closely associated with PD, these
numbers are even higher, especially for visual hallucina-
tions. Auditory hallucinations are present in up to
20%.52 Hallucinations can have substantial psychosocial
effects and historically constitute the main reason to place
patients in nursing homes.53 The pathophysiology of psy-
chosis in PD and Lewy body dementia involves a complex
interplay of extrinsic and disease-related factors, including
central dopaminergic overactivity and an imbalance of do-
paminergic and cholinergic neurotransmission, dysfunc-
tion of the visual pathways, alterations of brainstem
sleep-wake and dream regulation, and impaired atten-
tional focus.53 The most important extrinsic factor, how-
ever, is medication. The treatment of hallucinations in PD
involves patient-initiated coping strategies, a reduction of
antiparkinson medication, augmentation with low-dose
atypical neuroleptics, and, potentially, with cholinesterase
inhibitors. Eng and Welty54 conducted a review of
13 studies on antipsychotic treatment for PD patients,
all involving clozapine and quetiapine. They concluded
that patients with PD may benefit from long-term
clozapine therapy, whereas the results of the quetiapine
studies were conflicting. Various open-label studies and
one double-blind placebo-controlled trial involving 188
hallucinating PD patients are in support of the efficacy
of rivastigmine. Thus, while the use of cholinesterase
inhibitors, especially rivastigmine, appears to be a promis-
ing treatment for hallucinations in PD, evidence-based
studies support only the use of clozapine.54
In Alzheimer’s disease (AD), the occurrence of psycho-
sis in 30% to 50% of the cases has serious consequences
for both patients and caregivers,55 especially since the op-
timal type of treatment is still elusive. Interventions that
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optimize environmental and interpersonal factors should
be attempted in all cases, although their overall effective-
ness and applicability are not entirely clear. Cholinester-
ase inhibitors such as donepezil may have a beneficial
effect on hallucinations, while showing a relatively
mild side effect profile.56 In a similar vein, memantine
has been shown to be more effective than placebo
treatment without causing any disturbing side effects.
The Clinical Antipsychotic Trials of Intervention
Effectiveness-Alzheimer’s Disease (CATIE-AD) study
included 421 AD outpatients with psychosis and agitated
and/or aggressive behavior. The patients were random-
ized to obtain masked flexible-dose treatment with olan-
zapine, quetiapine, risperidone, or placebo for up to 36
weeks. As regards the effects on psychotic symptoms, ris-
peridone appeared to be superior to the other 2 drugs and
placebo.57 Although antipsychotic medication can have
a positive effect on hallucinations in dementia, several
reports issue warnings against the excess risk of morbid-
ity and even death associated with its use in older
patients. As a consequence, it is strongly advised not
to consider antipsychotic drugs as the first choice for
treatment of psychotic symptoms in dementia. Extrapy-
ramidal symptoms and arrhythmias due to QTc prolon-
gation are well-known complications of the use of
conventional antipsychotic agents, while cerebrovascular
events appear to occur more frequently in association
with atypical as well as conventional antipsychotics in
comparison with placebo treatment. Nevertheless, a trial
of these agents may be indicated when the severity of
symptoms is extreme or when symptoms fail to respond
to other types of medication or to nonpharmacological
interventions.
Delirium is an acute neuropsychiatric syndrome, by
definition due to organic disease, which is characterized
by psychotic symptoms such as hallucinations and delu-
sions in the presence of decreased attention, fluctuating
consciousness, and other cognitive dysfunctions. It is
very common in patients admitted to intensive care units,
with a reported cross-sectional frequency of 32%, and
a marked association with poor prognosis and increased
mortality.58 The only causal treatment of delirium is the
improvement of somatic health. The symptomatic treat-
ment of hallucinations and other symptoms of delirium
should commence with measures aimed at improving the
patient’s circadian rhythm and orientation. Pharmaco-
logical treatment should preferably consist of haloperidol
or olanzapine, as recommended by the latest NICE
guidelines.46 Although benzodiazepines are widely ap-
plied for the treatment of delirium, they are recommen-
ded only for delirium tremens (ie, alcohol abstinence
delirium). Cholinesterase inhibitors are not recommend-
able, as demonstrated by an RCT with rivastigmine in
delirious patients admitted to an intensive care unit.
This trial was terminated at an early stage because of sig-
nificant higher mortality and an increased duration of de-
lirium in comparison with the control group.59
The reported cross-sectional incidence of hallucina-
tions and other psychotic symptoms in epilepsy is
3.3%, and in temporal lobe epilepsy as high as 14%.60
Hallucinations can occur shortly before (aura), during
(ictal), or after an epileptic seizure, but frequently occur
independently of any motor seizures. Ictal hallucinosis is
considered relatively rare. Postictal hallucinations com-
prise some 25% of the hallucinatory episodes in epileptic
patients. As post and interictal psychotic episodes resem-
ble those in patients diagnosed with schizophrenia, they
are also designated as ‘‘schizophrenia-like psychoses of
epilepsy.’’ The treatment of ictal as well as post and inter-
ictal hallucinations should primarily consist of minimiz-
ing any medication capable of mediating these
symptoms. Various antiepileptic drugs, such as pheno-
barbital, zonisamide, levetiracetam, and gabapentin,
are known for their potential to induce hallucinations.62
In such cases, dose reduction or switching to another an-
tiepileptic drug may lead to a relatively quick cessation of
hallucinations. When antiepileptic drugs cannot be re-
duced or traded or when such an intervention is unsuc-
cessful, antipsychotic medication is the next therapeutic
step. Clozapine and chlorpromazine should be avoided
because of their epileptogenic properties.61 Antipsy-
chotics such as quetiapine, risperidone, and haloperidol
are usually well tolerated.
Visually impaired patients may experience complex vi-
sual hallucinations, a condition known as the Charles
Bonnet syndrome. Likewise, individuals with progressive
hearing loss may develop auditory hallucinations consist-
ing of music, voices, or other sounds. It is believed that
such hallucinations are actually release phenomena due
to a deafferentation of the visual or auditory association
areas of the cerebral cortex, a process capable of yielding
so-called ‘‘phantom percepts.’’62 Cognitive defects and
social isolation may act as additional risk factors. Release
hallucinations generally affect the elderly; women more
frequently than men. Patients who comprehend their un-
realistic nature tend to be affected less severely by them,
although they may still be distressed by the fear of immi-
nent insanity. Reassurance and an explanation that the
visions or auditory percepts do not imply any kind of
mental illness may have a powerful therapeutic effect.63
Further therapeutic measures are not always necessary
because release hallucinations may cease either spontane-
ously or upon the termination of social isolation. If war-
ranted and possible, the treatment of first choice is the
restoration of sight or hearing, for example by carrying
out a cataract operation, cleaning the meatus externus or
applying hearing aids. In addition, one may consider the
optimization of visual or auditory stimuli. When inter-
ventions such as these are unsuccessful, pharmacological
treatment may be considered, although the pros do not
always outweigh the cons of side effects. Antipsychotics,
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antiepileptics, and cholinesterase inhibitors have been
reported to be effective in case reports and open-label
case series. There are currently no randomized trials on
the efficacy of those types of medication in patients
with release hallucinations. If pharmacological treatment
is considered necessary, low-dose quetiapine or lamotri-
gine may be a good choice as it is usually tolerated well
in elderly populations.63 rTMS has also been applied to
this type of release hallucinations in the auditory domain,
but results are inconclusive.64
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